Bayesian interim analysis of phase II cancer clinical trials

Many popular sequential phase II clinical trial designs optimize some criterion subject to constraints on the error probabilities at null and alternative values of the response rate. Such designs may forfeit optimality if one fails to conduct analyses strictly according to plan. Moreover, a decision...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Statistics in medicine 1997-08, Vol.16 (16), p.1791-1802
1. Verfasser:	Heitjan, Daniel F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bayes Theorem Biological and medical sciences Clinical Trials, Phase II as Topic - methods Computerized, statistical medical data processing and models in biomedicine Cytarabine - administration & dosage Humans Idarubicin - administration & dosage Leukemia, Myeloid - drug therapy Medical sciences Medical statistics Models, Statistical Research Design Vidarabine - administration & dosage Vidarabine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!